MeSH term
Frequency | Condition_Probility | Adolescent | 33 | 0.0 |
Adult | 127 | 0.0 |
Aged | 89 | 0.0 |
Female | 164 | 0.0 |
Humans | 278 | 0.0 |
Hypertrophy, Left Ventricular/*etiology | 2 | 50.0 |
Male | 166 | 0.0 |
Middle Aged | 126 | 0.0 |
Parathyroid Hormone/*blood | 53 | 63.0 |
*Renal Dialysis | 14 | 3.0 |
Biological Markers/blood | 13 | 0.0 |
Case-Control Studies | 6 | 0.0 |
Child | 22 | 0.0 |
Collagen/*blood | 2 | 9.0 |
English Abstract | 24 | 0.0 |
Linear Models | 3 | 0.0 |
Osteocalcin/*blood | 6 | 27.0 |
Parathyroid Hormone/blood | 71 | 46.0 |
Peptide Fragments/*blood | 5 | 6.0 |
Sensitivity and Specificity | 3 | 0.0 |
Calcium/blood | 43 | 20.0 |
Kidney Failure, Chronic/complications | 3 | 15.0 |
Parathyroid Hormone/*blood/physiology | 4 | 80.0 |
Radioimmunoassay | 22 | 1.0 |
Aged, 80 and over | 26 | 0.0 |
Bone Density | 10 | 7.0 |
Bone and Bones/*metabolism | 11 | 15.0 |
Lumbar Vertebrae/metabolism | 2 | 33.0 |
Osteoblasts/*metabolism | 2 | 3.0 |
Parathyroid Hormone/blood/*secretion | 5 | 83.0 |
Radius/metabolism | 2 | 66.0 |
Research Support, Non-U.S. Gov't | 128 | 0.0 |
Blood Urea Nitrogen | 2 | 3.0 |
Bone Diseases, Metabolic/etiology | 2 | 50.0 |
Multivariate Analysis | 2 | 0.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
Phosphorus/blood | 10 | 29.0 |
Predictive Value of Tests | 2 | 0.0 |
Retrospective Studies | 4 | 0.0 |
Risk Factors | 5 | 0.0 |
Hypercalcemia/*etiology | 3 | 27.0 |
Alkaline Phosphatase/blood | 30 | 20.0 |
*Parathyroidectomy | 4 | 30.0 |
Phosphates/blood | 13 | 25.0 |
Time Factors | 14 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Animals | 68 | 0.0 |
Base Sequence | 12 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Cells, Cultured | 11 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Cyclic AMP/metabolism | 10 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
Mice | 18 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Parathyroid Hormone-Related Protein | 14 | 15.0 |
Protein Biosynthesis | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 56 | 0.0 |
Calcitriol/*therapeutic use | 3 | 42.0 |
Osteocalcin/blood | 17 | 22.0 |
Comparative Study | 58 | 0.0 |
Cross-Sectional Studies | 14 | 1.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Renal Dialysis | 11 | 3.0 |
*Aging | 4 | 2.0 |
Glomerular Filtration Rate | 3 | 2.0 |
Hyperplasia | 4 | 1.0 |
Kidney/physiology | 2 | 3.0 |
Rats | 28 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 25 | 0.0 |
Models, Biological | 3 | 0.0 |
Biological Markers | 6 | 0.0 |
Estrogens/*pharmacology | 3 | 3.0 |
Administration, Oral | 6 | 0.0 |
Amino Acids/urine | 4 | 13.0 |
Creatinine/urine | 3 | 2.0 |
Drug Administration Schedule | 6 | 0.0 |
Drug Therapy, Combination | 4 | 0.0 |
Prospective Studies | 14 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Kidney Failure, Chronic/*complications/*therapy | 2 | 50.0 |
Parathyroid Hormone/*secretion | 3 | 60.0 |
Finland/epidemiology | 2 | 1.0 |
Prevalence | 6 | 0.0 |
Statistics, Nonparametric | 5 | 0.0 |
Vitamin D-Binding Protein/blood | 4 | 19.0 |
Genotype | 5 | 0.0 |
Hydroxycholecalciferols/blood | 3 | 27.0 |
Receptors, Calcitriol/genetics | 2 | 4.0 |
Aging/*physiology | 3 | 1.0 |
Child, Preschool | 11 | 0.0 |
Infant | 6 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Insulin-Like Growth Factor I/analysis | 3 | 2.0 |
Neoplasms/blood | 2 | 5.0 |
Kidney Failure, Chronic/*blood/therapy | 3 | 5.0 |
Regression Analysis | 12 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptor, Parathyroid Hormone, Type 1 | 2 | 14.0 |
Structure-Activity Relationship | 5 | 0.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Hormones/*blood | 3 | 2.0 |
Blood Proteins/analysis | 2 | 1.0 |
Body Mass Index | 8 | 0.0 |
Calcifediol/blood | 13 | 54.0 |
Calcitonin/blood | 3 | 10.0 |
Densitometry, X-Ray | 14 | 9.0 |
Diagnosis, Differential | 5 | 0.0 |
Mandible/pathology | 2 | 66.0 |
Parathyroidectomy | 8 | 34.0 |
Recurrence | 4 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Anthropometry | 2 | 0.0 |
*Nutritional Status | 2 | 2.0 |
Creatinine/blood | 10 | 3.0 |
Injections, Intravenous | 4 | 0.0 |
Strontium/*pharmacokinetics | 2 | 66.0 |
Indicators and Reagents | 2 | 0.0 |
Parathyroid Hormone/*pharmacology | 10 | 33.0 |
*Parathyroid Hormone-Related Protein | 2 | 40.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Proteins/*pharmacology | 3 | 4.0 |
Radioligand Assay | 2 | 0.0 |
Aluminum/blood | 2 | 33.0 |
Parathyroid Hormone/*blood/immunology | 3 | 75.0 |
Calcium, Dietary/administration & dosage | 4 | 57.0 |
Mice, Nude | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Calcium/*blood/urine | 3 | 100.0 |
Etidronic Acid/*therapeutic use | 2 | 50.0 |
Bone and Bones/metabolism | 3 | 5.0 |
Alkaline Phosphatase/*blood | 2 | 5.0 |
Bone Remodeling/*drug effects | 5 | 38.0 |
Isoenzymes/*blood | 2 | 4.0 |
Procollagen/blood | 5 | 17.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Signal Transduction | 2 | 0.0 |
Insulin-Like Growth Factor I/*metabolism | 2 | 1.0 |
Prognosis | 2 | 0.0 |
Testosterone/*blood | 2 | 0.0 |
Calcitriol/*blood | 8 | 34.0 |
Proteins/*metabolism | 3 | 0.0 |
Bone Remodeling/physiology | 2 | 15.0 |
Collagen/blood | 4 | 36.0 |
Insulin-Like Growth Factor Binding Protein 3/metabolism | 2 | 13.0 |
Peptide Fragments/blood | 10 | 9.0 |
Peptides/blood | 4 | 11.0 |
Osteoblasts/metabolism | 2 | 3.0 |
Parathyroid Hormone/*physiology | 4 | 36.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Up-Regulation | 2 | 0.0 |
Follow-Up Studies | 9 | 0.0 |
Hyperparathyroidism/surgery | 2 | 100.0 |
Incidence | 3 | 0.0 |
Longitudinal Studies | 4 | 0.0 |
Reference Values | 19 | 0.0 |
*Bone Density | 9 | 8.0 |
Follicle Stimulating Hormone/blood | 3 | 0.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Osteoporosis/*blood | 2 | 40.0 |
Biomechanics | 2 | 1.0 |
Bone Density/drug effects | 3 | 10.0 |
Bone Resorption/*drug therapy | 2 | 40.0 |
Diphosphonates/*pharmacology | 2 | 20.0 |
Drug Synergism | 5 | 0.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Rats, Wistar | 3 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Diet | 4 | 1.0 |
England/epidemiology | 2 | 3.0 |
Ethnic Groups | 2 | 0.0 |
Hypoparathyroidism/epidemiology | 2 | 100.0 |
India/ethnology | 2 | 2.0 |
Vitamin D/blood | 4 | 50.0 |
Vitamin D Deficiency/blood/*epidemiology | 2 | 100.0 |
Cell Extracts | 2 | 1.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Cholecalciferol/*metabolism | 3 | 25.0 |
DNA Footprinting | 3 | 1.0 |
Dimerization | 3 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Oligonucleotides/metabolism | 2 | 2.0 |
Parathyroid Hormone/*genetics | 7 | 38.0 |
Receptors, Calcitriol/genetics/*metabolism | 2 | 6.0 |
Receptors, Retinoic Acid/genetics/metabolism | 2 | 6.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
*Response Elements | 2 | 3.0 |
Retinoid X Receptors | 2 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Transfection | 3 | 0.0 |
Body Weight | 3 | 0.0 |
Bone Remodeling | 3 | 15.0 |
Estradiol/blood | 3 | 0.0 |
*Menopause | 3 | 5.0 |
Calcium/metabolism | 7 | 0.0 |
Proteins/*analysis | 3 | 2.0 |
*Bone Resorption | 2 | 10.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Parathyroid Hormone/blood/*pharmacology | 2 | 100.0 |
Aldosterone/blood | 2 | 1.0 |
Double-Blind Method | 6 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Bone and Bones/pathology | 2 | 9.0 |
Vitamin D/administration & dosage | 3 | 42.0 |
Bone and Bones/*drug effects/metabolism | 2 | 28.0 |
Hyperparathyroidism, Secondary/blood/*drug therapy/etiology | 2 | 100.0 |
*Circadian Rhythm | 2 | 0.0 |
Cross-Over Studies | 3 | 0.0 |
Phosphates/blood/urine | 2 | 66.0 |
Calcium/blood/urine | 6 | 50.0 |
Hyperparathyroidism/blood/etiology | 2 | 66.0 |
Minerals/metabolism | 3 | 25.0 |
Binding, Competitive | 2 | 0.0 |
Calcitriol/pharmacology | 5 | 4.0 |
Mutation | 3 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Biological Markers/blood/urine | 4 | 8.0 |
Chronic Disease | 3 | 0.0 |
Collagen/urine | 3 | 16.0 |
Peptides/urine | 2 | 12.0 |
Biopsy | 9 | 0.0 |
Isoenzymes/blood | 3 | 4.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Parathyroid Glands/metabolism/*pathology | 2 | 50.0 |
*Dietary Supplements | 3 | 5.0 |
Adenylate Cyclase/metabolism | 4 | 2.0 |
RNA, Messenger/analysis | 3 | 0.0 |
*Bone Remodeling | 2 | 25.0 |
Bone Resorption | 7 | 19.0 |
Calcitriol/blood | 17 | 34.0 |
Calcium, Dietary/*administration & dosage | 2 | 40.0 |
Calcium/*blood | 13 | 14.0 |
Hyperparathyroidism/*blood | 2 | 33.0 |
Kidney/metabolism | 2 | 0.0 |
Phosphates/metabolism | 5 | 6.0 |
Bone Density/*drug effects | 4 | 13.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
Allopurinol/therapeutic use | 2 | 11.0 |
Gout/*blood/drug therapy | 2 | 100.0 |
Gout Suppressants/therapeutic use | 2 | 50.0 |
Absorption | 3 | 2.0 |
Aging/metabolism | 2 | 1.0 |
Analysis of Variance | 5 | 0.0 |
Bone Density/physiology | 3 | 14.0 |
Seasons | 3 | 2.0 |
Interleukin-1/pharmacology | 4 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Blotting, Southern | 7 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 11 | 6 | 0.0 |
Genetic Markers | 2 | 0.0 |
Biological Markers/urine | 2 | 3.0 |
Parathyroid Glands/*physiopathology | 2 | 66.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Receptors, Calcitriol/*genetics | 2 | 0.0 |
Breast Feeding | 2 | 3.0 |
Calcium/*metabolism | 12 | 1.0 |
Parathyroid Hormone/blood/*physiology | 3 | 75.0 |
European Continental Ancestry Group | 4 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Hyperparathyroidism, Secondary/*drug therapy/*etiology | 2 | 66.0 |
Blotting, Western | 2 | 0.0 |
Kidney/physiopathology | 2 | 3.0 |
Osmolar Concentration | 3 | 0.0 |
Biological Markers/*blood | 3 | 1.0 |
Exercise/*physiology | 2 | 0.0 |
Serum Albumin/metabolism | 3 | 1.0 |
Bone and Bones/*metabolism/radiography | 3 | 60.0 |
Cattle | 6 | 0.0 |
Cell Line | 5 | 0.0 |
Chromatography, Gel | 4 | 0.0 |
Intraoperative Period | 2 | 3.0 |
Parathyroid Glands/*secretion | 2 | 100.0 |
Biological Markers/analysis | 3 | 0.0 |
Blood Chemical Analysis | 4 | 8.0 |
Immunoradiometric Assay | 4 | 3.0 |
Phosphorus/blood/urine | 2 | 66.0 |
Bone Density/*physiology | 8 | 15.0 |
*Seasons | 2 | 5.0 |
Culture Media | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Species Specificity | 3 | 0.0 |
Chickens | 3 | 0.0 |
Hypercalcemia/chemically induced | 2 | 50.0 |
Hyperparathyroidism, Secondary/*drug therapy | 2 | 100.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Parathyroid Hormone/metabolism | 3 | 15.0 |
RNA, Messenger/genetics | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Bone and Bones/*pathology | 2 | 22.0 |
Hydrolysis | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Parathyroid Hormone/*metabolism | 8 | 38.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Models, Structural | 2 | 1.0 |
Parathyroid Hormone/genetics | 4 | 25.0 |
Restriction Mapping | 2 | 0.0 |
Calcitonin/*genetics | 2 | 33.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Osteocalcin/metabolism | 2 | 7.0 |
Hyperparathyroidism, Secondary/physiopathology | 2 | 100.0 |
In Vitro | 3 | 0.0 |
Evaluation Studies | 4 | 0.0 |
Phosphates/*blood | 3 | 33.0 |
Secretory Rate/drug effects | 2 | 2.0 |
Hyperparathyroidism/*drug therapy | 2 | 100.0 |
Peptide Fragments/pharmacology | 3 | 1.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 2 | 1.0 |
Carrier Proteins/*blood | 2 | 0.0 |
Insulin-Like Growth Factor Binding Proteins | 2 | 5.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Kidney/*metabolism | 6 | 3.0 |
Liver/*metabolism | 2 | 0.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Perfusion | 3 | 1.0 |
Teriparatide | 6 | 37.0 |
Calcitonin/*blood | 3 | 4.0 |
Acute Disease | 2 | 0.0 |
Osteitis Deformans/blood/*drug therapy | 3 | 100.0 |
Bone Resorption/metabolism | 2 | 16.0 |
Bone Resorption/diagnosis | 2 | 66.0 |
Blood Pressure/drug effects | 3 | 0.0 |
Pilot Projects | 2 | 0.0 |
Hydroxyproline/urine | 5 | 27.0 |
Organ Culture Techniques | 2 | 0.0 |
Osteogenesis/*drug effects | 2 | 18.0 |
Peptide Fragments/blood/*secretion | 2 | 40.0 |
DNA/analysis | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Globins/genetics | 3 | 2.0 |
*Linkage (Genetics) | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Kinetics | 6 | 0.0 |
Parathyroid Hormone/physiology | 2 | 28.0 |
Phosphorus/*blood | 4 | 66.0 |
Bone Remodeling/*physiology | 3 | 12.0 |
Hypercalcemia/blood | 3 | 75.0 |
Hypocalcemia/blood | 2 | 50.0 |
Culture Techniques | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Transforming Growth Factors/pharmacology | 2 | 11.0 |
Dogs | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Radioimmunoassay/*methods | 4 | 5.0 |
Rats, Inbred Strains | 6 | 0.0 |
Parathyroid Hormone/analysis | 2 | 50.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Calcium/*urine | 6 | 18.0 |
Hydroxylation | 2 | 0.0 |
Parathyroid Hormone/immunology | 4 | 100.0 |
Indomethacin/pharmacology | 3 | 1.0 |
Parathyroid Hormone/pharmacology | 4 | 14.0 |
Chromatography, Affinity | 2 | 0.0 |
Molecular Weight | 4 | 0.0 |
Chromosome Mapping | 8 | 0.0 |
Vitamin D/*blood | 2 | 12.0 |
Magnesium/blood | 2 | 9.0 |
Phosphates/urine | 2 | 22.0 |
Calcium/*pharmacology | 2 | 2.0 |
Cyclic AMP/urine | 8 | 50.0 |
Hydroxycholecalciferols/*blood | 3 | 37.0 |
Calcitonin/pharmacology | 4 | 18.0 |
*Kidney Transplantation | 3 | 0.0 |
Minerals/*metabolism | 3 | 30.0 |
Osteocalcin | 4 | 30.0 |
Genes, ras | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Hypercalcemia/*blood | 3 | 75.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Bone Resorption/*drug effects | 2 | 33.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
*Genes, Structural | 2 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Calcium-Binding Proteins/blood | 2 | 40.0 |
Parathyroid Hormone/biosynthesis/*genetics | 2 | 33.0 |
Kidney Function Tests | 2 | 1.0 |
Osteoporosis/*drug therapy/pathology | 2 | 66.0 |
Half-Life | 2 | 0.0 |
Hyperparathyroidism/*blood/surgery | 3 | 100.0 |
Receptors, Parathyroid Hormone | 2 | 28.0 |
Calcium/urine | 4 | 15.0 |
Linkage (Genetics) | 2 | 0.0 |
Hyperparathyroidism, Secondary/blood | 3 | 100.0 |
Hyperparathyroidism/*diagnosis | 2 | 66.0 |
Depression, Chemical | 2 | 1.0 |
Vitamin D/metabolism | 3 | 16.0 |
Dinoprostone | 2 | 2.0 |
Biological Assay | 2 | 0.0 |
Hyperparathyroidism/blood | 4 | 66.0 |
Kidney/enzymology | 2 | 1.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
*Chromosomes, Human, 6-12 and X | 2 | 1.0 |
Insulin/*genetics | 2 | 3.0 |
Metabolic Clearance Rate | 2 | 0.0 |
25-Hydroxyvitamin D 2 | 2 | 50.0 |
Ergocalciferols/analogs & derivatives/blood | 2 | 66.0 |
Immune Sera | 3 | 1.0 |
Hypoparathyroidism/blood | 2 | 66.0 |
Disease Models, Animal | 2 | 0.0 |
Uremia/blood | 2 | 11.0 |
